Abciximab
- Generic Name
- Abciximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143653-53-6
- Unique Ingredient Identifier
- X85G7936GV
- Background
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (Ξ±vΞ²3) receptor found on platelets and vess...
- Indication
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended ...
- Associated Conditions
- Ischemic cardiovascular events
- Associated Therapies
- -
EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-02-26
- Lead Sponsor
- Laval University
- Target Recruit Count
- 1000
- Registration Number
- NCT00169819
- Locations
- π¨π¦
Laval Hospital Research Center, Sainte-Foy, Quebec, Canada
Stroke Prevention With Abciximab in Carotid Endarterectomy
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- University of Rochester
- Registration Number
- NCT00178451
- Locations
- πΊπΈ
University of Rochester Medical Center- Strong Memorial Hospital, Rochester, New York, United States
Abciximab in Wake-up Stroke
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 50
- Registration Number
- NCT00167765
- Locations
- π¨π
University of Zurich, Department of Neurology, Zurich, Switzerland
π©πͺHeinrich Heine University, Dusseldorf, Germany
Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-09-12
- Lead Sponsor
- University Hospital Tuebingen
- Registration Number
- NCT00163254
- Locations
- π©πͺ
University of Tuebingen, Tuebingen, Germany
Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)
- Conditions
- Interventions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 800
- Registration Number
- NCT00133250
- Locations
- π©πͺ
Klinikum Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany
π©πͺFirst Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany
π¦πΉAllgemeines Krankenhaus Wien, Vienna, Austria
Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 2022
- Registration Number
- NCT00133003
- Locations
- π©πͺ
Deutsches Herzzentrum Muenchen, Munich, Germany
π©πͺFirst Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany
π³π±St. Antonius Ziekenhuis Hospital, Nieuwegein, Netherlands
Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 100
- Registration Number
- NCT00126139
- Locations
- π¨π
University of Geneva, Department of Neurology, Geneva, Switzerland
π¨πUniversity of Lausanne, Department of Neurology, Lausanne, Switzerland
π¨πUniversity of Bern, Department of Neurology, Bern, Switzerland
A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)
- Conditions
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 808
- Registration Number
- NCT00073372
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.